Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Unity Biotechnology Inc
UBX | US
1.40
USD0
0%
UBX | US
About Unity Biotechnology Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.40
Open
1.40
High
1.40
Low
1.38
Unity Biotechnology Inc. a biotechnology company engages in the research and development of therapeutics to slow halt or reverse diseases of aging. The company's lead drug candidate includes UBX1325 which is phase II clinical trial for the treatment of age-related diseases of the eye including diabetic macular edema age-related macular degeneration and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050 a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089 a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge Inc. and changed its name to Unity Biotechnology Inc. in January 2015. Unity Biotechnology Inc. was incorporated in 2009 and is headquartered in South San Francisco California.
View LessUBX | US
Risk
28.8
Sharpe
-0.70
Luna's Score
31/100
Recommendation
Sell
Luna says (UBX | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
35.0%1 month
28.8%3 months
41.5%6 months
46.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.19
Debt to equity
1.10
Debt to assets
0.40
Ent. to EBITDA
-0.23
Ent. to rev.
29.79
PEG
-
Other Fundamentals
EBITDA
-27.55M
MarketCap
23.59M
MarketCap(USD)
23.59M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-87.32
Short ratio
9.63
Short perc.
1.86
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.19
Range1M
0.19
Range3M
0.39
Volumes: Market Activity
Rel. volume
0.51
Price X volume
26.64K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.23 | - | Cheaper |
| Ent. to Revenue | 29.79 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.19 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 41.50 | - | Lower Risk |
| Debt to Equity | 1.10 | -1.23 | Expensive |
| Debt to Assets | 0.40 | 0.25 | Expensive |
| Market Cap | 23.59M | - | Emerging |
